Supernus Pharmaceuticals Inc. Company Profile
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The companyâs extensive expertise in product development has been built over the past 20 years: initially as a stand alone development organization, then as a U.S. subsidiary of Shire plc and, upon its acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals. The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy, ADHD and depression. In addition to its two ADHD product candidates, Supernus is developing two late stage epilepsy product candidates, SPN-538 (extended release topiramate), and Epliga® (extended release oxcarbazepine).
News Articles
Supernus raises $75 million in note deal
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) raised $75 million through the sale of 7.5% senior secured convertible notes. The notes mature on May 1, 2019, and initially convert at $5.30. Supernus prop...
Supernus raises $48 million in follow-on
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) raised $48 million through the sale of 6 million shares at $8 in a follow-on underwritten by Jefferies; Piper Jaffray; Cowen; Stifel Nicolaus Weisel; and La...
After 2 Drug Approvals, Can Supernus Deliver In 2013?
ByC.R. Jackson:Supernus Pharmaceuticals (SUPN) is developing a central nervous system (CNS) portfolio with proprietary extended release technologies. While most shareholders are investing in S...
FDA approves Supernus' epilepsy drug
FDA approved Oxtellar XR from Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) as an adjunctive therapy for epilepsy in adults and children 6-17 years old. The company plans to launch the once-daily extend...
Supernus proposes $75M note deal
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) said late Wednesday it plans to raise $75 million through the sale to institutional investors of convertible senior secured notes due 2019. Earlier this yea...
Supernus pharma deals for $90 million private placement financing
Supernus Pharmaceuticals pharma deals closing an announced private offering of $90 million financing. The net proceeds from this pharma deals financing offering were approximately $86.4 million, after...
Supernus Secures Financing For CNS Pipeline Development
By Alpha Cardinal:Supernus Pharmaceuticals, Inc. (SUPN) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. I...
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) is planning to raise up to $86.3 million in a follow-on underwritten by Jefferies; Piper Jaffray; Cowen; Stifel Nicolaus Weisel; and Lazard. Supernus, which...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is focused on developing specialty CNS products designed to address unmet medical needs. The companyâs portfolio is well diversified wit...
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseas...
Headquartered in Rockville, MD, Supernus Pharmaceuticals, Inc. (formerly Shire Laboratories) is a specialty pharmaceuticals company that has a broad portfolio of proven and patented drug delivery tech...
More Information about "Supernus Pharmaceuticals Inc." on BioPortfolio
We have published hundreds of Supernus Pharmaceuticals Inc. news stories on BioPortfolio along with dozens of Supernus Pharmaceuticals Inc. Clinical Trials and PubMed Articles about Supernus Pharmaceuticals Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Supernus Pharmaceuticals Inc. Companies in our database. You can also find out about relevant Supernus Pharmaceuticals Inc. Drugs and Medications on this site too.
